Atea Pharmaceuticals (AVIR) to Announce Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Atea Pharmaceuticals to post earnings of ($0.56) per share and revenue of $33.03 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Atea Pharmaceuticals Price Performance

AVIR opened at $4.62 on Thursday. The firm has a fifty day moving average price of $4.58 and a 200 day moving average price of $4.81. The stock has a market cap of $369.74 million, a P/E ratio of -2.19 and a beta of 0.31. Atea Pharmaceuticals has a 1 year low of $2.78 and a 1 year high of $6.45.

Institutional Trading of Atea Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of AVIR. JPMorgan Chase & Co. raised its stake in shares of Atea Pharmaceuticals by 118.6% in the 4th quarter. JPMorgan Chase & Co. now owns 1,348,294 shares of the company’s stock valued at $4,813,000 after acquiring an additional 731,443 shares during the period. Millennium Management LLC boosted its position in shares of Atea Pharmaceuticals by 179.2% during the 3rd quarter. Millennium Management LLC now owns 487,223 shares of the company’s stock worth $1,413,000 after purchasing an additional 312,733 shares during the period. Bank of America Corp DE increased its holdings in Atea Pharmaceuticals by 185.8% in the 3rd quarter. Bank of America Corp DE now owns 313,644 shares of the company’s stock valued at $910,000 after purchasing an additional 203,905 shares during the last quarter. Opaleye Management Inc. acquired a new stake in Atea Pharmaceuticals in the 4th quarter valued at approximately $642,000. Finally, Goldman Sachs Group Inc. raised its position in Atea Pharmaceuticals by 38.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 472,522 shares of the company’s stock valued at $1,687,000 after purchasing an additional 132,382 shares during the period. 86.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Atea Pharmaceuticals currently has a consensus rating of “Moderate Buy”.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.